Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,858.00
Bid: 6,847.00
Ask: 6,850.00
Change: 1.00 (0.01%)
Spread: 3.00 (0.04%)
Open: 6,800.00
High: 6,921.00
Low: 6,779.00
Yest. Close: 6,857.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 2-GSK warns on profits as weak lung drug sales hit

* 2014 EPS growth cut to "broadly flat" from 4-8 percent * Q2 sales 5.56 bln pounds vs consensus 5.76 bln * Q2 core EPS 19.1 pence vs consensus 21.3p * Shares fall more than 6 percent (Adds analyst reaction, CEO comments) By Ben Hirschler LONDON, July 23 (Reuters)

23 Jul 14 13:12

UPDATE 1-Top U.S. lawmaker wants corporate tax loophole 'plugged now'

(Adds Hatch comments, paragraphs 4-9) By Kevin Drawbaugh WASHINGTON, July 22 (Reuters) - Immediate government action is needed to stop U.S. corporations from avoiding federal taxes by shifting their tax domiciles overseas through deals known as inversions, the head of the U.S. Senate

22 Jul 14 16:56

CORRECT: AstraZeneca's MedImmune Teams With Advaxis For Cancer Trial

22 Jul 14 15:47

Top U.S. lawmaker wants corporate tax loophole 'plugged now'

By Kevin Drawbaugh WASHINGTON, July 22 (Reuters) - Immediate government action is needed to plug a loophole that allows U.S. corporations to avoid federal taxes by shifting their tax domiciles overseas through deals known as inversions, the head of the U.S. Senate Finance Committee said on

22 Jul 14 15:41

UK MIDDAY BRIEFING: Royal Mail's Parcels Business Fails To Deliver

22 Jul 14 11:34

RPT-U.S. Senate panel to debate wave of corporate tax-avoidance deals

(Repeats story published late on Monday and earlier on Tuesday) By Kevin Drawbaugh WASHINGTON, July 21 (Reuters) - As more U.S. corporations do deals to cut taxes by shifting their tax domiciles overseas, the Senate Finance Committee will hold a hearing on Tuesday focused on these tra

22 Jul 14 11:00

TOP NEWS: Bullish ARM Holdings Lifts Interim Dividend As Profits Rise

22 Jul 14 10:26

AstraZeneca's MedImmune Teams With Advaxis For Combined Cancer Trial

22 Jul 14 07:37

UK MORNING BRIEFING: Anglo American Leads Opening Gains

22 Jul 14 07:32

AstraZeneca widens cancer immunotherapy net with Advaxis trial

LONDON, July 22 (Reuters) - AstraZeneca is casting its net wider in the hot cancer immunotherapy field through a clinical trial collaboration with U.S. biotech firm Advaxis that will test drugs from both companies in combination. Britain-based AstraZeneca - the target of an unsuccessful $1

22 Jul 14 06:33

RPT-U.S. Senate panel to debate wave of corporate tax-avoidance deals

(Repeats story published late on Monday) By Kevin Drawbaugh WASHINGTON, July 21 (Reuters) - As more U.S. corporations do deals to cut taxes by shifting their tax domiciles overseas, the Senate Finance Committee will hold a hearing on Tuesday focused on these transactions known as inve

22 Jul 14 05:00

U.S. Senate panel to debate wave of corporate tax-avoidance deals

By Kevin Drawbaugh WASHINGTON, July 21 (Reuters) - As more U.S. corporations do deals to cut taxes by shifting their tax domiciles overseas, the Senate Finance Committee will hold a hearing on Tuesday focused on these transactions known as inversions. Nine such deals have been agreed

21 Jul 14 23:05

Drugmakers to share neglected compounds with British academia

LONDON, July 22 (Reuters) - A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening ties between industry and external scientists. British business minister Vince Cable anno

21 Jul 14 23:00

Broker tips: GlaxoSmithKline, AstraZeneca, Housebuilders

Panmure Gordon said it is "not expecting fireworks" from GlaxoSmithKline's (GSK) second-quarter results due out next Wednesday. "In light of our recent downgrade to forecasts due to exchange rate headwinds, we are expecting another tough quarter. China has not washed through completely either and g

18 Jul 14 12:23

Exane BNP Paribas expects Pfizer to return with better offer for Astra

Exane BNP Paribas sees at least a 50% chance that US pharmaceutical giant Pfizer will return with a sweetened offer for UK rival AstraZeneca (AZN) following its failed takeover earlier this year. The bank said it expects another approach in November, when restrictions under takeover panel rules exp

18 Jul 14 11:16

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.